Company: Sun Pharmaceutical Industries Ltd. Category: Company News

The total addressable market size for all these eight products is about $1 billion (according to recent IQVIA data) in mainland China
Aug. 16, 2019, 8:48 p.m.

To pay upfront fee of Rs 240 crore for potential development, regulatory and sales milestone
Aug. 14, 2019, 4:11 p.m.

The pact is for patents related to certain compounds with potential therapeutic activity across multiple indications
Aug. 14, 2019, 1:50 p.m.

Markets fear sustainability of performance; stock down over 5%
Aug. 14, 2019, 1:29 p.m.

Under the terms of the license agreement, Sun Pharma gets exclusive global license for the said patents and any other future patents covered in the agreement.
Aug. 14, 2019, 12:55 p.m.

India's largest drugmaker has raised focus on specialty and limited competition products in the wake of pricing pressure in the US
Aug. 13, 2019, 10:01 p.m.

Sun Pharmaceutical Industries on Tuesday reported a consolidated net profit of ₹1,387.48 crore for the quarter ended June 30, 2019. The company had p
Aug. 13, 2019, 4:40 p.m.

Sun Pharma had posted a profit of ₹1,057.29 crore for the corresponding period of the previous fiscal.Shares of Sun Pharmaceutical Industries were trading at ₹441 per scrip on BSE, up 4.53% from the precious close
Aug. 13, 2019, 4:20 p.m.

The company had posted a profit of Rs 1,057.29 crore for the corresponding period of the previous fiscal, Sun Pharma said in a filing to BSE
Aug. 13, 2019, 3:55 p.m.

US revenue would get impacted on qoq basis on account of derma segment facing competitive pressure.
Aug. 13, 2019, 10:05 a.m.